Skip to main content

Table 3 Correlation of MAPK immunoreactivity and mutational status of KRAS in low- and high-grade OSCs

From: P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas

 

Low-grade

High-grade

(No. of cases)

(No. of cases)

KRAS mutation

  

MAPK +

5

1

MAPK –

1

7

Wild KRAS

  

MAPK +

2

11

MAPK –

3

43

Total cases

11

62